TREATMENT OF ARTERIAL HYPERTENSION IN PREGNANT WOMEN
##semicolon##
Key words: hypotensive therapy, pregnancy, central hemodynamics.Abstrak
ABSTRACT
The purpose of this study was a comparative assessment of the effect of the
selective beta-1 adrenoblocker metoprolol, clonidine and methyldopa on the
hemodynamic parameters of the mother and the condition of the fetoplacental complex.
60 pregnant women with grade II hypertension and 20 healthy women were examined,
compared they differ in age and gestation period. The patients were divided into 3
clinically equivalent groups, the first of which received metoprolol 50 mg 2 times a
day as a hypotensive agent (with stabilization of the figures Blood pressure was
switched to a maintenance dose of 25 mg / day), the second – clonidine at a dose of
0.075 mg 2-3 times a day, the third – methyldopa 250 mg 2 times a day. The
effectiveness of treatment was assessed according to the data of echocardiography of
the mother, additional plerometry of the fetal placental vessels, fetal cardiotocography,
and the results of histological examination of the placentas. In the treatment of
hypertension in pregnant women with hyperkinetic type of central hemodynamics ,
metoprolol was more effective than clonidine and methyldopa in reducing blood
pressure, normalizing increased the indicators of the central hemodynamics of the
mother, restored blood flow in the fetoplacental system, increased the reactivity of the
fetal cardiovascular system. Clinical effects of clonidine have been noted in patients
current with hypokinetic type of central hemodynamics, methyldopa – with eukinetic
type of blood circulation preferences.
Antihypertensive therapy in pregnant women with hypertension should be
differentiated and dependent the network depends on the type of central
hemodynamics.
##submission.citations##
LITERATURE
1. Ziyadullaev, S. K., Sultonov, I. I., Dushanova, G. A., & Akbarovna, K. S.
(2021). The Effectiveness Of Pharmacotherapy For Dmards With Ra Depending
On The C3435t Polymorphism Of The Mdr1 Gene. Int. J. of Aquatic
Science, 12(3), 2908-2916.
2. Islomovich, S. I. (2024). GENDER CHARACTERISTICS OF THE CURRENT
RHEUMATOID ARTHRITIS. International journal of medical sciences, 4(10),
3-8.
3. Хамраева, Н. А., Султонов, И. И., & Хасанов, Ф. Ш. У. (2019). Кожные
проявления у больных системной красной волчанкой. Вопросы науки и
образования, (28 (77)), 128-131.
4. Sultonov, I. I., Kh, Z. S., Ruzybakieva, M. R., Kireev, V. V., Aripova, T. U., &
Suyarov, A. A. (2021). Pharmacogenetic Aspects of Drug Resistance in
Rheumatoid Arthritis. Annals of the Romanian Society for Cell Biology, 4147-
4150.
5. Kireev, V. V., & Sultonov, I. I. (2021). Genetic Engineered Preparations-An
Innovative Approach in the Treatment of Rheumatoid Arthritis. Annals of the
Romanian Society for Cell Biology, 4114-4119.
6. Hamraeva, N. A., Sultonov, I. I., & Hasanov, F. S. (2020). Systemic lupus
erythematosus treatment strategy. Journal of Critical Reviews, 7(9), 269-270.
7. Тоиров, А. Э., Султонов, И. И., & Тоиров, Э. С. (2020). ЗНАЧЕНИЕ
ДИСФУНКЦИИ ПОЧЕК У БОЛЬНЫХ ОСТРЫМ ИНФАРКТОМ
МИОКАРДА НА ФОНЕ САХАРНОГО ДИАБЕТА 2-ГО ТИПА. Вестник
науки и образования, (9-3 (87)), 86-91.
8. Иргашева, У. З., Султонов, И. И., & Тоиров, Д. Р. (2013). Признаки дебюта
системной красной волчанки. Академический журнал Западной
Сибири, 9(1), 15-15.
9. Xasanov, F. S., & Sultonov, I. I. (2023). RHEUMATOID ARTHRITIS
TREATED WITH DMARDS AND CARDIOVASCULAR DISEASE
RISK. Oriental Journal of Medicine and Pharmacology, 3(02), 45-52.
10. Нурматова, Л., Султонов, И., & Тоиров, Э. (2011). Эффективность
препаратов пищеварительной активности в комплексном лечении больных
хроническим гепатитом. Журнал проблемы биологии и медицины, (3 (66)),
107-110.
11. Sultonov, I. I., Khamrayev, X. X., & Xasanov, F. SYSTEMIC LUPUS
ERYTHEMATOSUS AND CARDIOVASCULAR PATHOLOGY: WHERE
WE AT?.
12. Sultonov, I. I., Xasanov, F. S., Eshmuratov, S., Uralov, R. S., Shukurova, D., &
Ziyadullayev, S. X. Predictors of Systemic Lupus Erythematosus: A Case-
control Study. International journal of health sciences, 6(S10), 175-182.
13. Khusainova, M. A., Toirov, D. R., Khaydarov, S. N., & Kamolova, D. D. (2023).
MORPHOFUNCTIONAL PARAMETERS OF THE HEART IN WOMEN
SUFFERING FROM ESSENTIAL ARTERIAL HYPERTENSION IN
POSTMENOPAUSE AND ON THE BACKGROUND OF
TREATMENT. Oriental renaissance: Innovative, educational, natural and
social sciences, 3(1), 322-330.
14. Djamshedovna, K. D., Alisherovna, K. M., Xudoyberdiyevich, G. X., &
Rustamovich, T. D. (2023). EFFECTIVENESS OF ANTIHYPERTENSIVE
THERAPY IN PREGNANT WOMEN. Spectrum Journal of Innovation,
Reforms and Development, 12, 137-144.
15. Alisherovna, K. M., Erkinovna, K. Z., Djamshedovna, K. D., &
Nizamitdinovich, K. S. (2023). QUALITY OF LIFE PATIENTS WITH
OSTEOARTHRITIS. Journal of new century innovations, 36(1), 164-175.
16. Djamshedovna, K. D., & Alisherovna, K. M. (2024). CHANGES IN SOME
SYSTEM INDICATORS IN PREGNANT WOMEN WITH
GESTOSIS. Spectrum Journal of Innovation, Reforms and Development, 25,
111-115.
17. Alisherovna, K. M., Erkinovna, K. Z., Djamshedovna, K. D., &
Nizamitdinovich, K. S. (2023). QUALITY OF LIFE PATIENTS WITH
OSTEOARTHRITIS. Journal of new century innovations, 36(1), 164-175.
18. Jamshedovna, K. D., Alisherovna, K. M., Erkinovna, K. Z., & Davranovna, M.
K. (2022). LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN
PREGNANT WOMEN WITH PRE-ECLAMPSIA WITHOUT
PROTEINURIA. Spectrum Journal of Innovation, Reforms and
Development, 10, 135-140.
19. Rustamovich, T. D., Alisherovna, K. M., Djamshedovna, K. D., &
Nizamitdinovich, K. S. (2023). Features of the psychoemotional status of
patients with rheumatoid arthritis. Miasto Przyszłości, 32, 23-30.
20. Alisherovna, K. M., Djamshedovna, K. D., Totlibayevich, Y. S., &
Boymamatovna, E. F. (2022). The Effectiveness of the Original Drug
Trimetazidine MV in Patients with Stable Ischemic Heart Disease and Persistent
Angina Attacks Against the Background of the Use of Trimetazidine
Generics. Miasto Przyszłości, 30, 235-238.
21. Alisherovna, K. M., & Djamshedovna, K. D. (2024). AFTER COVID-19
QUALITY OF LIFE. Spectrum Journal of Innovation, Reforms and
Development, 25, 103-110.
22. Alisherovna, K. M., Jamshedovna, K. D., Totlibayevich, Y. S., &
Xudoyberdiyevich, G. X. (2022). FEATURES OF THE QUALITY OF LIFE
OF PATIENTS WITH CHRONIC RENAL FAILURE IN THE TREATMENT
OF HEMODIALYSIS. Spectrum Journal of Innovation, Reforms and
Development, 7, 76-81.
23. Xudoyberdiyevich, G. X., Alisherovna, K. M., Rustamovich, T. D., &
Djamshedovna, K. D. (2023). QUALITY OF LIFE IN PATIENTS WITH
GOUT. Spectrum Journal of Innovation, Reforms and Development, 12, 156-
164.
24. Davranovna, M. K. D. K., Alisherovna, K. M., & Erkinovna, K. Z. (2024).
CARDIAC ARRHYTHMIAS IN PATIENTS WITH RHEUMATOID
ARTHRITIS. Spectrum Journal of Innovation, Reforms and Development, 26,
65-71.
25. Alisherovna, K. M., Ismatullayevich, M. A., & Nuriddinovna, E. N. (2024).
FEATURES OF HEART FAILURE IN PATIENTS WITH CORONARY
HEART DISEASE AND THYROTOXICOSIS. Ta'lim innovatsiyasi va
integratsiyasi, 19(4), 52-61.
26. Alisherovna, K. M., Yaxshiboyevich, U. M. R., & Yigitaliyevich, B. A. (2024).
EVALUATION OF A NATRIURETIC PEPTIDE TO OPTIMIZE THE
MANAGEMENT OF COMORBID PATIENTS WITH THYROTOXICOSIS
AND HEART FAILURE. Ta'lim innovatsiyasi va integratsiyasi, 19(4), 62-70.
27. Alisherovna, K. M., Erkinovna, S. D., Yazdonkulovna, X. M., & Zafarovna, C.
M. M. (2024). ATRIAL FIBRILLATION IN THYROTOXICOSIS–
DETERMINANTS OF DEVELOPMENT AND CONSERVATION. Ta'lim
innovatsiyasi va integratsiyasi, 19(4), 103-113. 28. Alisherovna, K. M., Mansurovna, M. D., Erkinovna, N. D., Farxodovna, X. R.,
Toxirovna, M. M., Tolibovna, R. D., & Yorkinovna, E. N. (2024). ARTERIAL
HYPERTENSION AND THYROID STATUS IN PATIENTS OF DIFFERENT
AGES. Ta'lim innovatsiyasi va integratsiyasi, 19(4), 122-129.
29. Alisherovna, K. M., Erkinovna, S. D., Duskobilovich, B. S., & Samandarovich,
T. H. (2024). ARTERIAL HYPERTENSION IN THYROTOXICOSIS AND
REMODELING OF THE LEFT VENTRICLE OF THE HEART. Ta'lim
innovatsiyasi va integratsiyasi, 19(4), 114-121.
30. Alisherovna, K. M., Habibulloyevna, I. M., & Voxidovna, R. F. (2024).
STRUCTURAL AND FUNCTIONAL FEATURES OF THE LEFT
VENTRICLE IN PATIENTS WITH HEART FAILUREIN ISCHEMIC
HEART DISEASE AND THYROTOXICOSIS. Ta'lim innovatsiyasi va
integratsiyasi, 19(4), 71-81.
